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BACKGROUND: The immunohistochemical (IHC) 4þC score is a cost-effective prognostic tool that uses clinicopathologic factors and
four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility in personalising breast cancer
treatment in a clinical practice setting, through comparison with Adjuvant! Online (AoL) and the Nottingham Prognostic Index (NPI).
METHODS: We prospectively gathered clinicopathologic data for postmenopausal patients with hormone receptor-positive,
HER2-negative, N0-3 resected early breast cancer treated consecutively at our institution. We retrospectively calculated and
compared prognostic scores. The primary endpoint was the proportion of patients reclassified from AoL-defined intermediate-risk by
application of the IHC4þC score.
RESULTS: The median age of the 101 patients included in the analysis was 63. In all, 15 of the 26 patients classified as intermediate-risk
by AoL were reallocated to a low-risk group by application of the IHC4þC score and no patient was reclassified as high-risk group.
Of the 59 patients classified as intermediate-risk group by the NPI, 24 were reallocated to a low-risk group and 13 to a high-risk
group.
CONCLUSION: IHC4þC reclassifies more than half of the patients stratified as being in intermediate-risk group by the AoL and NPI.
The use of IHC4þC may substantially improve decision-making on adjuvant chemotherapy.
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The majority of patients with early breast cancer are recommended
adjuvant systemic therapy after primary surgery to reduce risk of
breast cancer recurrence and to increase the likelihood of cure.
There is demonstrable benefit in the addition of adjuvant
chemotherapy to endocrine therapy in women with oestrogen
receptor (ER)-positive early breast cancer Early Breast Cancer
Trialists’ Collaborative Group (2005). However, patient selection is
important because some women may be successfully treated
with endocrine therapy alone, and spared the potentially serious
and quality of life diminishing toxicities of chemotherapy. The
proportion of patients in this group has increased markedly in
recent years owing to the earlier diagnosis of breast cancer and the
better prognosis disease that is associated with early detection.
Endocrine therapy has side effects, but is comparatively well
tolerated. The difficulty is in accurately stratifying which women
with early ER-positive, HER2-negative breast cancer can be spared
from chemotherapy. Combinations of prognostic and predictive
clinicopathologic factors have been developed into tools that
allocate patients into risk categories with the goal of improved
stratification.
The Nottingham Prognostic Index (NPI) is one of the earliest
tools to be developed (first presented in 1982, Haybittle et al, 1982;
Lee and Ellis, 2008). It was designed through retrospective
multivariate regression analysis in a study of 387 women with
primary, operable breast cancer and has been independently and
prospectively validated (Balslev et al, 1994; D’Eredita et al, 2001;
Blamey et al, 2007). It uses tumour size, grade and nodal burden
to classify patients into groups as good, moderate and poor
prognosis, with NPI o3.4, 3.4–5.4 and 45.4, respectively. The
original 15 year overall survival estimates for each prognostic
group of 80%, 42% and 13%, respectively, were based on data from
the 1980s (Galea et al, 1992). Updated survival estimates from the
1990s have been published together with additional divisions of the
prognosis groups (Table 1) (Blamey et al, 2007).
Adjuvant! Online (AoL) is a popular prognostic and predictive
tool freely available on the Internet (http://www.adjuvantonline.
com). It uses the same factors as the NPI as well as ER status, age
and comorbidity to project the likelihood of mortality and disease
recurrence at 10 years, and the magnitude of benefit to be gained
by adjuvant therapy for individual patients (Ravdin et al, 2001).
The prognostic information is predominantly based on data from
the Surveillance, Epidemiology and End-Results registry (http://
www.seer.cancer.gov), and the projections of efficacy of adjuvant
therapy are based on data from the Early Breast Cancer Trialists’
Collaborative Group overviews of randomised clinical trials (Early
Breast Cancer Trialists’ Collaborative Group, 1998a, b, 2005). It has
been independently validated using a large, population-based
database (Olivotto et al, 2005). Its ease of use and the personalised
information it generates, quantitatively estimating prognosis with
and without adjuvant therapy, are reasons for its popularity.
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An important recent focus for translational researchers has been
towards discovery of molecular markers that better predict
individual residual risk after endocrine therapy in patients with
ER-positive disease. A number of assays incorporating multiple
molecular markers have been developed chiefly for this purpose.
The Oncotype Dx or 21-gene recurrence score (RS) (Paik et al,
2004) is a multi-gene assay that tests for overexpression of 21
genes with reverse-transcriptase PCR (Paik et al, 2004). An
algorithm is used to calculate the RS and determine risk category
(low: o18, intermediate: X18–o31 or high: X31). The RS has
been validated in ER-positive breast cancer; in node-negative and
node-positive populations, and in tamoxifen-treated, AI-treated
and chemotherapy-treated populations (Habel et al, 2006;
Paik et al, 2006; Goldstein et al, 2008; Albain et al, 2010;
Dowsett et al, 2010). Prospective validation of the predicted
benefit from chemotherapy in the higher RS patients is taking
place in the TAILORx trial (Zujewski and Kamin, 2008). The
almost complete independence of the molecular risk information
from RS from the clinicopathologic information encompassed
in AoL means that more accurate risk estimates can be made
by integrating the two types of data (Goldstein et al, 2008;
Tang et al, 2011).
The immunohistochemical (IHC) 4þC score is a prognostic
tool based on quantitative values of four standard laboratory
assays (ER, PR, HER2 and Ki67), and the clinicopathologic
parameters of tumour grade, size, nodal burden, patient age, and
treatment with AI or tamoxifen (hence IHC4þ clinical (IHC4þC)
score) (Cuzick et al, 2011). The IHC4þC score was developed in a
retrospective analysis from TransATAC after recognition that
these IHC assays independently hold prognostic power in
endocrine-treated patients (Dowsett et al, 2008; Dowsett et al,
2011b). IHC4þC gives a prediction of the residual risk of
distant recurrence at 9 years in postmenopausal women with
node-negative, hormone receptor-positive disease treated with
5 years of adjuvant endocrine therapy (Cuzick et al, 2011).
The score’s performance was found to contain a comparable
degree of prognostic information to the RS using the TransATAC
data set, and was validated in an independent data set.
Further assessment to establish broader applicability was advised
(Cuzick et al, 2011).
Like many other institutions, we use AoL to assist in decision-
making concerning adjuvant systemic therapy. For women with
ER-positive breast cancer with good or intermediate prognosis, we
calculate the predicted benefit of chemotherapy in addition to
endocrine therapy and use this in making treatment recommenda-
tions. The objective of this study was to compare the prognostic
information gained from IHC4þC with that from the AoL and
NPI, in a group of postmenopausal women with early breast cancer
receiving treatment at our institution, to determine whether
assessment of IHC4þC assists in the selection of patients who
may be safely treated with adjuvant hormone therapy alone and
spared the side-effects of chemotherapy.
PATIENTS AND METHODS
Patient population
We prospectively recorded post-operative clinicopathologic data
for women with early breast cancer consecutively presenting to our
single institution during 1 year (February 2010 to February 2011).
Patients were included if they had hormone receptor-positive,
HER2-negative early breast cancer that was either node-negative or
pathological stage N1 (1–3 axillary lymph nodes containing
macrometastases (deposit X2mm)), and had undergone surgery
to remove the breast tumour, with tumour-free surgical margins.
Patients receiving neoadjuvant therapy were excluded. Patients
with axillary lymph nodes containing micrometastases were
classified as not involved. HER2-negative was defined as being
HER2 0 or 1þ on IHC staining or IHC2þ , and either
chromogenic or fluorescence in-situ-hybridisation (CISH or FISH)
negative (Wolff et al, 2007). Only postmenopausal women were
included, because the IHC4-C score has not yet been fully validated
in premenopausal women. Postmenopausal was defined as women
X60 years of age or X50, and amenorrhoeic for 12 months in the
absence of hysterectomy or intrauterine contraceptive device
(IUCD) or endocrine therapy, or women who had undergone
bilateral oophorectomy, or in women aged 50–59 whose meno-
pausal status was indeterminate such as because of hysterectomy
or IUCD, in whom there was biochemical evidence (elevated FSH
and suppressed oestradiol) of menopause. Patient age was
recorded at the time when the decision on the patient’s adjuvant
management was made. Women over the age of 75 were excluded.
Women who had incomplete axillary staging or no axillary staging
surgery performed were excluded, as were women with bilateral
breast cancer, due to anticipated unreliable prognostic estimations
of both IHC4þC and AoL in these settings.
Study design
The study was a retrospective comparison of the AoL, NPI and
IHC4þC score, to determine whether the IHC4þC contributed to
decision-making concerning adjuvant therapies. Clinicopathologic
data was collected prospectively over the 1-year period, after which
the IHC4þC score, AoL and the NPI were retrospectively
compared. The study was approved by our institution’s clinical
audit committee.
Study endpoints
The primary endpoint was the proportion of patients reallocated
from AoL-defined intermediate risk of distant recurrence at 10
years, to either high or low risk, by application of the IHC4þC
score. The first secondary endpoint was the proportion of patients
reallocated from NPI-defined moderate risk to either high or low
risk, by application of the IHC4þC score. Other secondary
endpoints were correlation between AoL and IHC4þC, correlation
between the NPI and IHC4þC, and correlation between the NPI
and AoL.
The immunohistochemical (IHC)4þC
We incorporated standard IHC tests on formalin-fixed paraffin-
embedded breast tumour tissue in combination with clinicopatho-
logic factors of tumour grade, size, nodal burden, patient age and
AI treatment in calculating the IHC4þC score for each patient,
using the same laboratory methods that were described by the
TransATAC research group in deriving the IHC4 other than for
Ki67, where the MIB1 antibody was used instead of SP6 after
establishing their close similarity (Zabaglo et al, 2010; Cuzick et al,
2011). The ER was quantified by the H-score, which is defined as
the percentage of cells showing weak IHC staining, added to two
Table 1 NPI 10-year breast cancer-specific survival (1990–1999; Blamey
et al, 2007)
Prognostic group
NPI (0.2 tumour
size (cm)þ gradeþ
nodal status (pN0¼ 1,
pN1-3¼2, pNX4¼ 3)
10-year
survival
(%)
Extremely good prognostic group (EPG) 2.08–2.4 96
Good prognostic group (GPG) 2.42–p3.4 93
Moderate prognostic group I (MPGI) 3.42–p4.4 81
Moderate prognostic group II (MPGII) 4.42–p5.4 74
Poor prognostic group (PPG) 5.42–6.4 50
Very Poor prognostic group (VPPG) 6.5–6.8 38
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times the percentage of cells staining moderately, added to three
times the percentage of cells staining intensely that was then
divided by 30 to arrive at variable between 0–10 (ER10). An H-score
of more than 1 is positive. PgR was quantified by the percentage of
cells staining positive, and this was divided by 10 to obtain a
variable between 0 and 10 (PgR10). HER2 assessment was given as
either a positive (IHC3þ or IHC2þ and CISH or FISH positive) or
negative result (IHC0 or 1þ or 2þ and CISH or FISH negative).
Ki67 was quantified as the percentage of positively staining cancer
cells, using the MIB1 antibody (Zabaglo et al, 2010).
The IHC4 score was calculated by the algorithm:
94:7f 0:100 ER10 0:079 PgR10þ 0:586HER2
þ 0:240 ln ð1þ 10Ki67Þg
As was described in the published methods for assessing IHC4 in
the independent validation cohort (Cuzick et al, 2011), we also
multiplied Ki67 by 0.4 to scale for the difference in scoring
technique. This is because Ki67 scores are on average 2.5 times
higher with manual reading than using the image analysis method
from which this algorithm was derived.
The clinical score was calculated by the published algorithm:
100f0:417N1 3þ 1:566N4þ þ 0:930 ð0:497T1 2þ 0:882T2 3
þ 1:838T4 3þ 0:559Gr2þ 0:970Gr3þ 0:130Age650:149AnaÞg;
with Nj, Tj, Grj and Agej representing categories of nodal status,
tumour size, grade and patient age, respectively, and Ana
representing treatment with anastrozole as opposed to tamoxifen.
The IHC4þC score was the sum of the IHC4 and the clinical score.
Adjuvant! Online
We prospectively calculated AoL predictions of mortality and
recurrence for each patient and entered this into our database.
We collected information regarding patient comorbidity, but
owing to the large differences in breast cancer-specific mortality
predicted by AoL when conditioned for competing mortality risk
and also because neither the IHC4þC score nor NPI corrects for
competing mortality risk, we decided a priori to use an assumption
of perfect health for all patients. We used ‘adjuvant AI for 5 years’
in assessing the predicted effectiveness of adjuvant endocrine
therapy. We took the prediction of death from breast cancer at 10
years and subtracted the additional benefit conferred by 5 years
adjuvant endocrine therapy to calculate the residual risk of breast
cancer mortality at 10 years despite adjuvant endocrine therapy.
Nottingham Prognostic Index
The NPI was calculated for each patient postoperatively, and was
based on operative pathological findings. The NPI score is 0.2
tumour size (cm)þ gradeþ nodal status (pN0¼ 1, pN1-3¼ 2,
pNX4¼ 3). Patients with an NPI o3.4 are considered to be at
low risk, 3.4–5.4 at intermediate risk and 45.4 at high risk.
Statistical analysis
The 9-year residual distant recurrence risk after adjuvant
endocrine therapy estimate generated by IHC4þC score was
corrected to 10 years (assuming a constant recurrence event rate).
The 10-year breast cancer-specific mortality after endocrine
therapy that was generated from AoL was multiplied by 1.25, to
arrive at a figure representing 10-year residual distant breast
cancer recurrence risk after adjuvant endocrine therapy. The
multiplier of 1.25 was derived through comparison of distant
recurrence and breast cancer-specific survival outcomes in
patients treated with 5 years of adjuvant tamoxifen or anastrozole
monotherapy in the ATAC study, where the number of distant
recurrence events at 10 years was 25% greater than the number of
breast cancer-specific mortality events at 10 years (Cuzick et al,
2010). The distant recurrence risk at 10 years after adjuvant
endocrine therapy was chosen so the two tools can be directly
compared. It also correlates with RS and meant that similar cutoffs
between risk groups used could be applied to our results. We used
cutoffs of 10 and 20% risk of distant recurrence at 10 years because
these correspond with the 18 and 30 RS risk of distant recurrence
at 10 years that is used to classify patients as being at intermediate
risk, which has been used in previous comparisons (Goldstein
et al, 2008; Dowsett et al, 2010; Tang et al, 2011).
The relationship between AoL and IHC4þC was assessed on a
continuous basis graphically and by Spearman’s Rank correlation.
The Stuart–Maxwell test of marginal homogeneity was used to test
for significant differences between the prognostic scores using
Stat 11.2 for windows. All patients meeting eligibility criteria were
included in these analyses. The planned sample size was 100
patients, which was estimated to be a representative number and
attainable within our single institution. It also meant that an odds
ratio of approximately three could be detected, assuming there
were 40% discordant pairs.
RESULTS
Patient and disease characteristics
Two hundred and four patients were considered potentially eligible
for the study on the basis of having hormone receptor-positive,
HER2-negative early breast cancer and p3 axillary lymph
nodes containing metastases. In all, 84 patients were excluded
due to clinical eligibility factors (5 had bilateral breast cancer,
2 were male, 15 were aged 475 years, 59 were premenopausal,
3 had unstaged axillary lymph nodes). One hundred and twenty
patients met eligibility criteria for the study. In all, 19 patients were
not able to be included due to difficulty in obtaining tissue from a
different centre or IHC4þC processing difficulty, leaving a total of
101 evaluable patients. The patient demographic and clinicopatho-
logic characteristics are summarised in Table 2. The median
patient age was 63, and the median tumour size was 20mm.
Comparison between AoL score and IHC4þC score
Figure 1 shows the agreement between AoL and IHC4þC
estimates of risk of distant recurrence at 10 years. The Spearman’s
Rank correlation was 0.84. Overall AoL rated patients at higher risk
than IHC4þC. Agreement between the categories created for the
IHC4þC score and the AoL score was 68.3% (95% CI:
58.3–77.2)(Table 3). Within the AoL-defined intermediate-risk
group, 58% of patients were reclassified by application of the
IHC4þC. Risk was lower by IHC4þC, with 15/26 patients
reclassified as low risk, 11/26 remaining classified as intermediate
risk and no patient reclassified as high risk. IHC4þC also
frequently restratified patients from an AoL-defined high-risk
group to a low-risk group. Forty-seven percent of the patients in
the AoL-defined high-risk group were downgraded; 13/32 to
intermediate-risk group and 3/32 to low-risk group by the use of
IHC4þC. In contrast, the risk stratification was found to be highly
consistent between the low-risk groups, with 41/43 patients
stratified by AoL as low-risk being also stratified as low-risk by
IHC4þC. Only two patients were reclassified from low to
intermediate-risk by the use of IHC4þC, and none were
reclassified to high-risk.
Comparison between the NPI and IHC4þC score
The correlation between the IHC4þC and NPI score risk groups
was 60.4% (95% CI: 50.2–70.0; Table 4). The IHC4þC restratified
the majority of the patients (37/59) in the NPI-defined inter-
mediate-risk group to either a high- or low-risk group. Just over
IHC4þC in clinical practice in early breast cancer
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one-third of these patients (24/59) were moved from an inter-
mediate to a low-risk group, 13/59 were moved to high-risk and 22/59
remained in the intermediate-risk group. Only 3/38 patients in the
NPI low-risk group were reclassified by IHC4þC as intermediate-
risk and none as high-risk. Only four patients were classified as high-
risk group by NPI as none of our patients hadX4 nodes positive and
few had grade 3 tumours, and in these circumstances only a very
large tumour gives an NPI of 45.4 (high risk).
Correlation between AoL and NPI score
There was moderate correlation between the AoL and NPI at 65.3%
(95% CI: 55.2–74.5; Table 5). The predominant category where
there was disagreement was in the NPI-defined intermediate-risk
group, with 28/55 patients classified as intermediate-risk by
NPI being reallocated to a high-risk group by AoL. Only four
patients were classified as high-risk group by both NPI and AoL.
The greatest agreement was seen in the low-risk group, with
37 patients classified low-risk by both NPI and AoL.
DISCUSSION
We found in an oncology clinical practice setting that IHC4þC
provides additional stratification regarding the residual risk of
distant recurrence in ERþ primary breast cancer patients to
receive adjuvant endocrine therapy, supplementary to that
provided by the AoL and NPI intermediate-risk groups. The
IHC4þC score downgraded more than half of the patients in the
AoL-defined intermediate-risk group to a low-risk group. Nearly
two-thirds in the NPI-defined intermediate-risk group were
reallocated into either a low- or high-risk group, with risk
stratification most often lowered. The risk category changes we
observed indicate that the use of IHC4þC in the clinical setting
would often lead to a change in adjuvant treatment decisions with
an overall increase in the number of patients who may safely be
Table 2 Demographic and clinicopathologic characteristics of the study
population
Factor
Number of
patients (N¼ 101)
Age
50–59 35 (35%)
60–69 50 (49%)
70–75 16 (16%)
Tumour size (mm)
o20 48 (48%)
20–49 46 (46%)
X50 7 (7%)
Tumour grade
1 15 (15%)
2 62 (61%)
3 24 (24%)
Axillary nodal stage
N0 (negative) 82 (81%)
N1 (1–3 nodes positive) 19 (19%)
ER status (H score)
o10 1 (1%)
10–99 8 (8%)
100–199 49 (49%)
X200 43 (43%)
PR status (%)
o5 22 (22%)
5–39 24 (24%)
40–79 25 (25%)
X80 30 (30%)
Ki67%
o10 41 (41%)
10–19 36 (36%)
X20 24 (24%)
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Figure 1 Spearman’s Rank correlation between AoL and IHC4þC
estimates of risk of distant recurrence at 10 years.
Table 3 Comparison of IHC4þC score with Adjuvant! Online in
assessing residual risk of distant recurrence at 10 years after adjuvant
endocrine therapy
IHC4-C
Low Intermediate High
Adjuvant! Online
Low, 0–10.0% 41 2 0
Intermediate, 410.0–20.0% 15 11 0
High, 420.0% 3 12 17
Agreement: 68.3% (95% CI: 58.3–77.2), Po0.001.
Table 4 Comparison of the IHC4þC score with the NPI in assessing
risk of breast cancer distant recurrence
IHC4-C
Low,
0–10.0%
Intermediate,
410.0–20.0%
High,
420.0%
NPI
Low (o3.4) 35 3 0
Intermediate (3.4–5.4) 24 22 13
High (45.4) 0 0 4
Agreement: 60.4% (95% CI: 50.2–70.0), Po0.001.
Table 5 Comparison of Adjuvant! Online with the NPI in assessing risk
of distant recurrence
Adjuvant! Online
Low,
0–10.0%
Intermediate,
410.0–20.0%
High,
420.0%
NPI
Low (o3.4) 37 1 0
Intermediate (3.4–5.4) 6 25 28
High (45.4) 0 0 4
Agreement: 65.3% (95% CI: 55.2–74.5), Po0.001.
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spared unnecessary adverse effects of chemotherapy. This extra
information based on biological phenotype would be valuable
for decision-making concerning adjuvant chemotherapy in a
substantial proportion of patients.
The correlation between two different tools has been evaluated
previously to compare prognostic and predictive efficacy, and to
determine whether one tool adds independent information to the
other. Our results are similar to that seen when other risk-
projecting tools have been equated with another. For instance,
comparisons of Oncotype Dx with AoL have demonstrated that
these prognostic tools each provide discrete prognostic informa-
tion, with relatively poor congruency (Goldstein et al, 2008;
Dowsett et al, 2010; Tang et al, 2011). In spite of this,
experimentation with combining these two prognostic tools into
one integrated tool has not yet been shown to be useful, although
more information was gained in one study by the integration of
common clinicopathologic factors with Oncotype Dx (Tang et al,
2011). The fact that the information contributed by clinicopatho-
logic factors was complementary to that obtained by molecular
analysis alone is relevant to the present study, as the IHC4þC also
combines surrogate information via IHC about the individual
molecular profile of the tumour, and combines it with common
clinicopathologic factors. The prognostic information provided by
IHC4þC on top of that from clinicopathologic features has
previously been shown to be at least as great as the additional
information provided by Oncotype Dx (Cuzick et al, 2011).
Our method of deriving predicted 10-year breast cancer-specific
survival from AoL is different from that used by two other groups
of authors (Dowsett et al, 2010; Tang et al, 2011). They used the
AoL estimate of breast cancer-specific mortality without compet-
ing risks at 10 years follow-up (shown as ‘10-year risk’), which is
not corrected for comorbidity. The mortality projections made by
AoL are otherwise markedly affected by comorbidity (Ozanne et al,
2009). However, we accounted for the discrepancy by using
‘perfect health’ as the comorbidity status of all patients. Therefore,
the only varying difference between the ‘10-year risk’ figure and
our estimate of breast cancer-specific mortality at 10 years is a
small adjustment that AoL makes according to each patient’s age.
We observed that the 10-year breast cancer-specific survival
estimates we calculated were very similar to the ‘10-year risk’. Our
method of adjusting the AoL breast cancer-specific survival
estimate into a distant recurrence risk estimate, using data from
the ATAC study to calculate a simple multiplication factor, was a
pragmatic approach to enabling direct comparison of the
prognostic tools. We acknowledge that there may be minor
variance between true AoL risk estimate and the AoL risk estimate
we generated as a consequence of using this method, but would
anticipate this to be relatively trivial.
A major advantage of IHC4þC is its cost-effectiveness, being
considerably less expensive than gene expression profiling tools
such as Oncotype Dx. Another major advantage of IHC4þC over
Oncotype Dx is that it uses existing laboratory assays, and in
principle it could therefore be performed at the majority of
oncology clinical centres internationally. On the other hand, there
are quality assurance issues with qualitative assessment of ER, PR,
HER2 and Ki67% IHC, with the potential for interlaboratory
variation in values. Although international groups are making
efforts to standardise these assays (Wolff et al, 2007; Hammond
et al, 2010), there remains justifiable concern. Ki67% in particular
has caused apprehension due to variable methods of assessment
and heterogeneity in results between different laboratories.
However, following a focused working group meeting in which
investigators with expertise in assessment of Ki67% made recom-
mendations aimed towards standardising Ki67 methodology and
reducing interlaboratory variability; the Ki67% assay results are likely
to become better synchronised between laboratories (Dowsett et al,
2011a). The IHC4þC score has been validated using a separate data
set with IHC assays that were evaluated in a different laboratory.
However, for the IHC4þC score to be validated comprehensively to
ensure its reliability and reproducibility, it would need to be tested
more widely, with assays conducted in several different laboratories
(Cuzick et al, 2011). Our study adds to the literature with further
evidence of Ki67 being reliably assayed with the results being utilised
successfully in clinical practice.
Our results show that the IHC4þC score does not appear to be
additionally useful in patients classified by AoL or the NPI to be of
low-risk, as there was high correlation between the two scores in
these categories, and no patients were moved from AoL or NPI-
defined low-risk to a high-risk group by IHC4þC. IHC4þC holds
predictive information as well as prognostic, as by estimating
residual risk after endocrine therapy it is partially predicting
endocrine therapy benefit. However, even those patients who fail
to gain substantial benefit from endocrine therapy are likely to
remain at relatively low risk of recurrence, such that adjuvant
chemotherapy risk would probably outweigh benefit. These results
indicate that patients assessed as low-risk by AoL or NPI are
unlikely to benefit from the supplementary prognostic information
provided by IHC4þC and should be recommended adjuvant
endocrine therapy alone.
Judging by our findings, it is possible that IHC4þC has clinical
utility in the AoL high-risk group. IHC4þC downgraded just less
than half of the patients from a high-risk stratification by AoL to
intermediate-risk or even, in a few, to a low-risk stratification. IHC4
correlates reasonably closely with Oncotype Dx (72%) (Cuzick et al,
2011), and for this reason it is likely to also be predictive of the
magnitude of benefit from chemotherapy in the same way that
Oncotype Dx is demonstrated to be (Paik et al, 2006; Albain et al,
2010). The additional information regarding risk stratification
provided by IHC4þC for patients at AoL-defined high-risk, but
intermediate or low-risk by IHC4þC, may be beneficial by predicting
less chemosensitivity and/or greater benefit from endocrine therapy,
which could contribute to decisions on adjuvant therapy.
It appears that AoL may overestimate risk compared with the
IHC4þC and NPI. A similar phenomenon was noticed in a
comparison of AoL with Oncotype Dx (Dowsett et al, 2010). A
reason why AoL may predict a higher level of risk compared with
IHC4þC is that it is based on clinical data that was mainly
collected in the era preceding breast screening, and may
disproportionately convey risk statistics associated with breast
cancers that are biologically more aggressive, whereas IHC4þC is
based on outcomes from a low-risk breast cancer population.
There was a low frequency of patients stratified as high-risk by
NPI compared with AoL and IHC4þC. This is likely to be because
our study population was confined to patients with p3 lymph
nodes, and hormone receptor-positive disease (which is less often
grade 3 than triple-negative breast cancer). In this context, tumour
size must be large for NPI risk category to be high. IHC-4 and AoL
are influenced by a greater number of variables, resulting in wider
division of risk group allocation in this low- and intermediate-risk
hormone receptor-positive population.
In conclusion, we found that IHC4þC assisted with risk
stratification in the challenging group of patients with early
breast cancer classified as being of intermediate-risk by the AoL
and NPI. More than half of the patients classified as being of
intermediate-risk by the AoL and NPI were reclassified by IHC4þC.
This study is important for providing evidence that IHC4þC
may be useful in guiding decision-making regarding adjuvant
chemotherapy in an oncology clinical practice setting.
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